Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Next Previous
Trial Profile

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Avid Radiopharmaceuticals

Most Recent Events

  • 04 Aug 2022 Results of retrospective analysis of the AV-1451-A16 (n=60) presented at the Alzheimer's Association International Conference 2022
  • 28 May 2020 Results published in the U.S. Food and Drug Administration Media Release.
  • 28 May 2020 According to an U.S. Food and Drug Administration media release, it has approved Tauvid (flortaucipir F18) for intravenous injection under Priority Review. It is the first drug used to help image a distinctive characteristic of Alzheimer's disease in the brain called tau pathology. The safety and effectiveness of Tauvid imaging was evaluated in two clinical studies, Study 1 (NCT02516046) and Study 2 (NCT03901092).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top